Drug Profile
Research programme: monomethyl fumarate prodrugs - Alkermes plc
Alternative Names: AKLS-MMF; ALKS MMF; MMF prodrug program - Alkermes; RDC-1559Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Alkermes plc
- Class Fumarates; Small molecules
- Mechanism of Action Immunomodulators; NF E2 related factor 2 stimulants; NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in Ireland (PO, Controlled release)
- 17 Jul 2013 Preclinical trials in Multiple sclerosis in Ireland (PO)